# reload+after+2024-01-21 14:46:03.881587
address1§1000 Skokie Boulevard
address2§Suite 350
city§Wilmette
state§IL
zip§60091
country§United States
phone§847 388 0349
website§https://www.monopartx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
fullTimeEmployees§11
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc', 'age': 39, 'title': 'Co-Founder, CEO, President & Director', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 708125, 'exercisedValue': 0, 'unexercisedValue': 397992}, {'maxAge': 1, 'name': 'Ms. Kim R. Tsuchimoto CPA', 'age': 60, 'title': 'CFO, Secretary, Treasurer & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 350550, 'exercisedValue': 0, 'unexercisedValue': 105468}, {'maxAge': 1, 'name': 'Mr. Andrew J. Cittadine M.B.A.', 'age': 51, 'title': 'Chief Operating Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 390406, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Patrice P. Rioux M.D., Ph.D.', 'age': 72, 'title': 'Acting Chief Medical Officer', 'yearBorn': 1951, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.817
currency§USD
dateShortInterest§1702598400
forwardEps§-0.58
exchange§NCM
quoteType§EQUITY
shortName§Monopar Therapeutics Inc.
longName§Monopar Therapeutics Inc.
firstTradeDateEpochUtc§1576765800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§4c85e6c0-debc-355c-95b2-bf3324d36ecc
gmtOffSetMilliseconds§-18000000
targetHighPrice§15.0
targetLowPrice§2.0
targetMeanPrice§8.5
targetMedianPrice§8.5
recommendationMean§2.5
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§4.286
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
